The current state and future directions for donor selection (sex, age, ABO blood type, and HLA disparity), donor source, the dose of infused CD34+ cells, optimal conditioning, and the concomitant graft-versus-host disease prophylaxis other than PTCY are also extensively discussed. This evidence concerns the gene ABO and graft versus host disease.